All
Gene-based treatment provides sustained AMD therapy
July 1st 2016The first clinical trial of lentiviral gene therapy in ophthalmology met its primary objective, demonstrating safety and tolerability of subretinal administration of a lentiviral vector expressing anti-angiogenic proteins in patients with advanced exudative age-related macular degeneration.
Gene therapy in RPE65 trial offers promise for improved vision
June 13th 2016The first randomized, controlled phase III gene therapy trial that is investigating treatment with adeno-associated viral vector delivery of human RPE65 in patients with RPE65 mutation-associated inherited retinal dystrophies is discussed.
Sonepcizumab combination therapy may offer long-term visual acuity stabilization
June 13th 2016Sonepcizumab alone or in combination with anti-VEGF does not provide any short-term benefit to the visual acuity in patients with wet AMD, who were considered to be subresponders to anti-VEGF therapy. However, a combination of therapies may have different results.
Electroretinography detects early glaucoma signs
June 8th 2016Lesions appear in both outer and inner retinal layers in the early onset of glaucoma, with the most pathological change in neurophysiological processes affecting the photoreceptors cells of the outer layer. Such findings could aid in early diagnosis of the disease.
Diabetic retinopathy debate resurfaces with new perspectives
May 9th 2016The debate over pharmacologic therapy versus laser treatment for diabetic eye disease is back. The players are different–anti-VEGF agents and panretinal laser photocoagulation instead of anti-VEGF agents and macular laser photocoagulation.
Tie2 activator augments anti-VEGF for DME
May 4th 2016Results from TIME-2, a phase IIA study, support further development of combination treatment with subcutaneous injection of the Tie2 activator, AKB-9778 (Aerpio Therapeutics), plus intravitreous (IVT) anti-VEGF injection for diabetic macular edema.
Anti-VEGF shows benefits for CNV with rare diseases
May 4th 2016Intravitreous injection with ranibizumab (Lucentis, Genentech) is well-tolerated, safe, and improves the functional and anatomic status in patients with visual impairment due to choroidal neovascularization (CNV) associated with rare diseases, according to findings from 6 months of follow-up in the phase III MINERVA study.
DME therapy with plasma kallikrein inhibitor showing promise
May 3rd 2016Results from a phase I study of KVD001 (KalVista Pharmaceuticals) for the treatment of central involved diabetic macular edema (CIDME) show that this plasma kallikrein inhibitor was well-tolerated, not associated with any ophthalmic or systemic safety signals, and led to fairly long-lasting improvements in visual acuity (VA) and central retinal thickness (CRT) after a single intravitreous injection.
Outer retinal layer thickness predicts visual acuity in diabetic macular oedema
February 29th 2016Diabetes mellitus is a common health problem in developed countries, with diabetic macular oedema (DMO) being a major cause of visual loss. A variety of treatment modalities for DMO are available including laser, steroid and intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Viral-mediated gene therapy approaches for retinal degeneration
February 25th 2016Kimberly Drenser, MD, PhD, explains that there is hope for treating these patients with the advent of viral-mediated, gene replacement therapy and new synthetic replacement molecules for inherited retinal degenerations.